RNS Number : 0769Q
Kromek Group PLC
13 December 2024

13 December 2024

Kromek Group plc
("Kromek" or the "Group")

Result of AGM

Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed.

Details of the proxy voting results, which should be read alongside the Notice of AGM, are below:

Resolution	Votes for*		Votes against		Votes withheld	Total proxy votes
	No. of votes	*% of votes cast***	*No. of votes*	*% of votes cast***	*No. of votes*	
1	207,344,859	93.58	14,216,844	6.42	214,790	221,776,493
2	219,607,384	99.44	1,240,099	0.56	929,010	221,776,493
3	218,684,712	99.50	1,093,449	0.50	1,998,332	221,776,493
4	219,546,698	99.64	784,563	0.36	1,445,232	221,776,493
5	217,710,854	98.85	2,543,519	1.15	1,522,120	221,776,493
6	202,085,251	91.31	19,229,668	8.69	670,309	221,985,228
7	208,955,888	94.64	11,827,699	5.36	992,906	221,776,493

*Includes discretionary votes

**Excludes withheld votes

For further information, please contact:

Kromek Group plc
Arnab Basu, CEO
Paul Farquhar, CFO
+44 (0)1740 626 060

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance
Tim Redfern - ECM
Michael Johnson/Tamar Cranford-Smith - Sales
+44 (0)20 7220 0500

Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble
+44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGEAAADFFNLFFA